What is the first-line medication for the management of idiopathic intracranial hypertension?

The first-line medication for the management of idiopathic intracranial hypertension is acetazolamide. This carbonic anhydrase inhibitor effectively reduces cerebrospinal fluid (CSF) production, leading to a decrease in intracranial pressure. Acetazolamide helps alleviate the symptoms associated with this condition, such as headaches and visual disturbances, by directly addressing the pathophysiological mechanism behind the increased intracranial pressure.

Additionally, acetazolamide is often chosen because it has a good safety profile and can be used long-term. Its efficacy in treating idiopathic intracranial hypertension is supported by clinical evidence and guidelines. Other treatment options may be considered for different situations, but acetazolamide remains the standard initial therapy.